Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Illumina (ILMN) Optics for Genomics -- Ignore unavailable to you. Want to Upgrade?

To: JakeStraw who wrote (272)	1/19/2017 4:33:20 PM
From: Steve Lokness	Respond to of 276

Wooh! The Roche news is old news for PACB now. .........The market cap for ILMN is 23Billion whereas the market cap for PACB is but 412 million. I don't think ILMN is worried very much by competition from PACB. But, and this is a big BUT, .........PACB with its long reads is more 'accurate' with fewer missing reads and without the gaps. Listen to recent CC from PACB if you want to get a feel for where PACB is going. I'm a bit surprised that ILMN hasn't gone after PACB - if for no other reason than they then wouldn't even have to look over the shoulder. PACB is cheap now - but maybe not so in the future should PACB hit their targeted goals for this year.